Bionano Genomics, Inc. — Cash Flow Charts
9 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow
$-3M
Free Cash Flow
$-3M
Investing Cash Flow↑+33.8% +$1M
$4M
Financing Cash Flow↓-58.8% -$2M
$2M
Capex
—
Acquisitions
—
Stock-Based Comp↓-52.2% -$1M
$926K
Debt Repaid
$18M
D&A↓-2.5% -$61K
$2M
SBC Allocated Expense↓-52.2% -$1M
$926K
SBC Unrecognized Cost
—